We identified and validated TMEM41B as a target of miR-660-5p in breast cancer cells, which aligns with previous findings that miR-660-5p promotes breast cancer progression by targeting TET2 and activating the PI3K/AKT/mTOR pathway [14] and the miR-660-5p/TFCP2/CDKN1A pathway [13]. Here, TFCP2 is linked to breast cancer.